Andre Witkin, MD

Title: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study To Assess The Efficacy And Safety Of Lampalizumab Administered Intravitreally To Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration

Brief Summary
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Inclusion Criteria

Study Requirements
2 year study with additional testing

Age Range
50 and over


$50 per visit

Transportation provided

Contact: Carly Satsuma, 617-636-5489